NCT01788189View on ClinicalTrials.gov

Lenalidomide, MTX, Ara-C and Rituximab in Relapsed Aggressive B-cell Lymphomas

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

37

Participants

Timeline

Start Date

January 31, 2013

Primary Completion Date

February 20, 2020

Study Completion Date

February 20, 2020

Conditions
B-cell Lymphoma
Interventions
DRUG

Lenalidomide

Trial Locations (1)

45147

Klinik für Hämatologie, Universitätsklinikum Essen, Essen

Sponsors

Collaborators (1)

Celgene
All Listed Sponsors
collaborator

Celgene

INDUSTRY

lead

University Hospital, Essen

OTHER

NCT01788189 - Lenalidomide, MTX, Ara-C and Rituximab in Relapsed Aggressive B-cell Lymphomas | Biotech Hunter | Biotech Hunter